Press Releases

Latest News & Archive

 
 
     
 
 
  2017
 
 
April 05, 2017
 
Affimed Presents Data on Immune Cell Engager Pipeline at the AACR Annual Meeting 2017
 
 
March 30, 2017
 
Affimed Reports Financial Results for Fourth Quarter and Year End 2016
 
 
March 23, 2017
 
Affimed Announces Fourth Quarter and Year End 2016 Financial Results and Corporate Update Conference Call
 
 
March 14, 2017
 
Affimed to Present at the Oppenheimer 27th Annual Healthcare Conference – New York
 
 
March 01, 2017
 
Affimed to Present Data on Immune Cell Engagers at the AACR Annual Meeting 2017
 
 
February 28, 2017
 
Affimed to Present at the Cowen and Company 37th Annual Health Care Conference
 
 
February 8, 2017
 
Affimed to Present at the Leerink Partners 6th Annual Global Healthcare Conference
 
 
January 25, 2017
 
Affimed Announces Closing of Public Offering of Common Stock
 
 
January 20, 2017
 
Affimed Announces Pricing of Public Offering of Common Stock
 
 
January 19, 2017
 
Affimed Announces Proposed Public Offering of Common Stock
 
 
January 11, 2017
 
Affimed Provides Update on NK-Cell Immuno-Oncology Platform
 
 
January 4, 2017
 
Affimed and MD Anderson Announce Clinical Immuno-Oncology Development Collaboration
 
 
  2016
 
     
 
December 6, 2016
 
Affimed Presents New Preclinical Data on Bi- and Trispecific Immune Cell Engagers at ASH
 
 
November 9, 2016
 
Affimed to Present at the Jefferies 2016 London Healthcare Conference
 
 
November 8, 2016
 
Affimed to Present Preclinical Data on Bi- and Trispecific Immune Cell Engagers at ASH
 
 
November 2, 2016
 
Affimed Reports Financial Results for Third Quarter 2016
 
 
October 31, 2016
 
Affimed to Present at the Credit Suisse 25th Annual Healthcare Conference
 
 
October 26, 2016
 
Affimed Announces Third Quarter 2016 Financial Results and Corporate Update Conference Call
 
 
October 4, 2016
 
Affimed Presents Preclinical Data on Lead Candidate AFM13 at the Annual Meeting of the Society for Natural Immunity
 
 
September 22, 2016
 
Affimed to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
 
 
September 1, 2016
 
Affimed to Present at Upcoming Investor Conferences
 
 
August 10, 2016
 
Affimed Reports Financial Results for Second Quarter 2016 and Provides Corporate Update
 
 
August 3, 2016
 
Affimed Announces Second Quarter 2016 Financial Results and Corporate Update Conference Call
 
 
May 31, 2016
 
Affimed to Present at the Jefferies 2016 Healthcare Conference
 
 
May 23, 2016
 
Affimed Announces Annual General Meeting of Shareholders
 
 
May 18, 2016
 
Affimed Reports Financial Results for First Quarter 2016
 
 
May 17, 2016
 
Affimed to Present at the UBS Global Healthcare Conference –New York
 
 
May 11, 2016
 
Affimed Announces First Quarter 2016 Financial Results and Corporate Update Conference Call
 
 
April 21, 2016
 
Affimed Presents Data on AFM13-mediated Innate/Adaptive Immune Crosstalk at the AACR Annual Meeting 2016
 
 
April 21, 2016
 
Affimed Presents Data on EGFRwt and EGFRvIII-targeting NK- and T-Cell TandAbs at the
AACR Annual Meeting 2016
 
 
March 30, 2016
 
Affimed Reports Financial Results for Fourth Quarter and Year End 2015
 
 
March 23, 2016
 
Affimed Announces Fourth Quarter and Year End 2015 Financial Results and Corporate Update Conference Call
 
 
March 17, 2016
 
Affimed to Present Data on NK- and T-Cell Engagers at the AACR Annual Meeting 2016
 
 
February 29, 2016
 
Affimed to Present at the Cowen and Company 36th Annual Health Care Conference
 
 
February 22, 2016
 
Affimed to Speak at Symposium on Emerging Approaches in Cancer Immunotherapy
 
 
February 04, 2016
 
Affimed to Present at the Leerink Partners 5th Annual Global Healthcare Conference
 
 
January 25, 2016
 
Affimed Enters into Collaboration with Merck to Evaluate AFM13 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Hodgkin Lymphoma
 
 
January 21, 2016
 
Affimed Appoints Dr. Joerg Windisch as Chief Operating Officer and Adds Dr. Bernhard Ehmer to Supervisory Board
 
 
January 20, 2016
 
Affimed to Host Hodgkin’s Lymphoma Day with Key Opinion Leaders on January 26th in New York
 
 
January 14, 2016
 
Affimed Announces Addition of Dr. Andrew Evens to Scientific Advisory Board
 
 
January 12, 2016
 
Affimed to Present at Noble Financial Capital Markets’ 12th Annual Investor Conference
 
 
  2015
 
 
December 14, 2015
 
Affimed Added to NASDAQ Biotech Index
 
 
December 6, 2015
 
Affimed Presents Additional Data on Combination of AFM13 with Checkpoint Inhibitors at ASH
 
 
December 6, 2015
 
Affimed Presents Data Comparing T-cell- and NK-cell-engaging TandAbs AFM11 and AFM12 at ASH
 
 
December 2, 2015
 
Affimed Announces Appointment of Andrew Curtis to Lead Corporate Strategy and Business Development,
Expansion of US Presence
 
 
December 1, 2015
 
Affimed to Present at the Oppenheimer 26th Annual Healthcare Conference –New York
 
 
November 11, 2015
 
Affimed CEO to Present at the Jefferies 2015 Global Healthcare Conference – London
 
 
November 10, 2015
 
Affimed Reports Financial Results for Third Quarter 2015
 
 
November 6, 2015
 
Affimed Presents Data on Potency of NK- and T-cell EGFRvIII TandAbs at SITC
 
 
November 5, 2015
 
Affimed to Present Data on NK- and T-Cell Engagers at ASH
 
 
November 3, 2015
 
Affimed Announces Third Quarter 2015 Financial Results and Corporate Update Conference Call
 
 
October 14, 2015
 
Affimed Announces Significant Investment by an Existing Shareholder
 
 
October 6, 2015
 
Affimed to Present Data on Potency of NK- and T-cell EGFRvIII TandAbs at SITC
,
 
September 23, 2015
 
Affimed to Present at the Leerink Partners Inaugural Immuno-Oncology Roundtable Conference
 
 
August 4, 2015
 
Affimed Reports Financial Results for Second Quarter 2015
 
 
July 28, 2015
 
Affimed Announces Second Quarter 2015 Financial Results and Corporate Update Conference Call
 
 
June 30, 2015
 
Affimed Added to Russell 2000® Index
 
 
June 23, 2015
 
Affimed Announces Opening of US Operations and Key US-based Hires
 
 
June 17, 2015
 
AbCheck and Pierre Fabre Pharmaceuticals Enter Into Strategic Research Partnership
 
 
June 3, 2015
 
Affimed Announces Newly Formed Scientific Advisory Board
 
 
May 29, 2015
 
Affimed ASCO Data Demonstrate Consistent Potency of NK-Cell- Engaging Combination Therapy
with Checkpoint Modulators
 
 
May 29, 2015
 
Affimed ASCO Data for the CD33/CD3-TandAb Program Demonstrate that CD33 and CD3
binding affinities correlate with potent T-cell activation and cytotoxicity
 
 
May 27, 2015
 
Affimed to Present at the Jefferies 2015 Healthcare Conference – New York
 
 
May 21, 2015
 
Affimed Reports Financial Results for First Quarter 2015
 
 
May 13, 2015
 
Affimed to Present Data at ASCO to Highlight Potency of NK-Cell-Engaging Combination Therapy with Checkpoint Modulators
 
 
May 13, 2015
 
Affimed Announces First Quarter 2015 Financial Results Conference Call
 
 
May 12, 2015
 
Affimed N.V. Announces Closing of Public Offering of Common Stock and Exercise of Underwriters’ Option to Purchase Additional Shares
 
 
May 12, 2015
 
Affimed N.V. Announces Shareholder Meeting
 
 
May 12, 2015
 
Affimed to Present at the UBS Global Healthcare Conference – New York
 
 
May 06, 2015
 
Affimed N.V. Announces Pricing of Public Offering of Common Stock
 
 
May 04, 2015
 
Affimed N.V. Announces Proposed Public Offering of Common Stock
 
 
March 25, 2015
 
Affimed Announces Financial Results for Fourth Quarter and Year End 2014
 
 
March 24. 2015
 
Affimed Completes TandAb Development Candidate Activities Meeting Amphivena’s and Janssen’s Criteria and Achieves Milestone Ahead of Schedule
,
 
March 18, 2015
 
Affimed Announces Fourth Quarter and Year End 2014 Financial Results Conference Call
 
 
March 03, 2015
 
Affimed to Present at the 27th Annual ROTH Conference
 
 
February 03, 2015
 
Affimed to Present at the BIO CEO & Investor Conference
and at the Leerink Partners Global Healthcare Conference
 
 
January 20, 2015  
Affimed Appoints Dr. Martin Treder as Chief Scientific Officer
 
 
January 07, 2015  
Affimed Receives EUR 2.4 million ($3 million) Research Grant from German Government
 
     
 
  Past Press Releases
2014 - 2010
         
 
  For more information contact:  
   
 

Caroline Stewart
Head Investor Relations

Phone: +1 34 73 94 67 93

IR@affimed.com
or
c.stewart@affimed.com

 

Dr. Anca Alexandru
Head of Communications

Phone: +49 62 21 64 79 33 - 41

a.alexandru@affimed.com

 
To be added to our press
release distribution system:
please klick here  
 
 
 
 



 
  Impressum Disclaimer